Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Navan Inc. Class A Common Stock (NAVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Navan Inc. Class A Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Navan Inc. Class A Common Stock trades at $24.06 (market cap $6.25B). The key difference: Navan Inc. Class A Common Stock is far larger — about 6.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Navan Inc. Class A Common Stock is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Navan Inc. Class A Common Stock for 6 Days on average.
| MRVI | NAVN | |
|---|---|---|
Market Cap | $977.37M | $6.25B |
Volume | 2,742,564 | 2,778,133 |
Sector | Health | Technology |
52-Week High | $9.00 | $30.58 |
52-Week Low | $2.83 | $8.51 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.08B | $5.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Navan (NAVN) trades at $23.9, up 1.44% on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported strong revenue growth of 35% year-over-year in Q2 2027 to $233 million, beating earnings expectations, yet remains unprofitable with a net income margin of -42.11%. Recent developments include the acquisition of BoomPop and a partnership with Engine to expand its AI-powered travel platform.
The outlook is mixed: unanimous analyst buy ratings and a $30.56 price target suggest 27.5% upside, driven by growth execution. However, high debt, persistent losses, insider selling, and ongoing legal investigations pose significant risks. The stock's valuation appears stretched given current profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Navan Inc. Class A Common Stock
Navan provides an AI-powered platform for business travel, payments, and expense management. Its tools support trip booking, policy controls, payment processing, expense reconciliation, and reporting.
Read more on NAVN →
